Skip to content

Risk and Protective Factors for Relapse to Alcohol Use in Patients With Liver Disease Undergoing Liver Transplantation

Risk and Protective Factors for Relapse to Alcohol Use in Patients With Alcohol-related Liver Disease and Undergoing Orthotopic Liver Transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06749990
Enrollment
320
Registered
2024-12-27
Start date
2024-01-09
Completion date
2030-12-31
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Related Liver Disease, Orthotopic Liver Transplantation

Brief summary

This is an observational, monocentric study, consisting of both a retrospective and a prospective component. The aim of the study is to identify risk and protective factors for alcohol relapse in patients with alcohol-related liver disease (ARLD) who have undergone orthotopic liver transplantation (OLT).

Detailed description

For the retrospective part of the study, clinical data will be collected and analyzed from patients diagnosed with ARLD and with components of exotoxicity who underwent liver transplantation in the past five years. This data will be obtained from patient medical records, including results from laboratory tests and multidisciplinary outpatient consultations conducted as part of routine clinical practice. The prospective phase of the study will involve the consecutive enrollment of patients diagnosed with ARLD or with exotoxicity-related etiological components who are undergoing liver transplantation at the IRCCS AOUBO. Four patient assessment points are planned, which will take place during routine follow-up visits already scheduled as part of the patient's care pathway. During these visits, data will be collected on the patient's medical history, laboratory and/or histological results, as well as diagnostic and surgical information. Additionally, through the administration of clinical questionnaires, data will be gathered on the patient's psychiatric-psychological status, history of exotoxicity, and psychosocial background.

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who have signed the informed consent * Candidates for liver transplantation due to liver disease with alcohol-related etiology (either mono- or multifactorial) * For the retrospective part: patients who underwent OLT for ARLD during the time frame 2017-2022

Exclusion criteria

* Major psychopathologies and active psychoses

Design outcomes

Primary

MeasureTime frameDescription
alcohol relapse rate7 yearsTo describe the population undergoing liver transplantation with a diagnosis of ARLD and exotoxicity-related components in terms of alcohol relapse rate
alcohol recurrence rate7 yearsTo describe the population undergoing liver transplantation with a diagnosis of ARLD and exotoxicity-related components in terms of alcohol recurrence rate
Clinical data to assess the risk of alcohol relapse7 yearsCollection of clinical data on liver disease through routine visits to assess the risk of alcohol relapse at 12 months post-OLT
psychiatric evaluation to assess the risk of alcohol relapse7 yearsAdministration of a clinimetric assessment composed of psychometric, self-assessment tests, already validated and widely used in the literature

Secondary

MeasureTime frameDescription
Impact of alcohol relapse/recurrence on liver transplant outcomes7 yearsTo assess the impact of alcohol relapse/recurrence on liver transplant outcomes.
Identifying Risk and Protective Factors for Alcohol Relapse7 yearsTo identify potential risk and protective factors for alcohol relapse and, consequently, to develop a multiparametric/multimodal operational model for evaluating candidates for liver transplantation

Countries

Italy

Contacts

Primary ContactMaria Cristina Morelli, MD
mariacristina.morelli@aosp.bo.it0512144248

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026